Can CAR‑T help people with multiple sclerosis?

Experimental CAR‑T shows early signs of benefit for some patients

Researchers have repurposed a cancer immunotherapy approach to target the autoimmune processes that drive multiple sclerosis. In a small number of people treated at specialised centres, clinicians used chimeric antigen receptor T‑cell (CAR‑T) therapy — an engineered immune‑cell treatment originally developed for blood cancers — to deplete or reprogram the immune cells thought to attack the nervous system.

Patients treated under experimental programmes have reported reductions in relapse activity and some improvement in symptoms months after infusion. Those outcomes are notable because current disease‑modifying therapies for relapsing and progressive MS reduce inflammation but do not reliably restore damage already done to the nervous system. CAR‑T’s mechanism — a deep reset of specific immune cells — offers a biological rationale for more durable disease control in people who have failed multiple standard treatments.

Important cautions remain.

• The evidence so far comes from early, small‑scale studies or case reports, not large randomised trials. Longer follow‑up is needed to judge how durable benefits are.
• CAR‑T carries known short‑term risks such as severe immune reactions, infections and organ toxicities; these risks can be life‑threatening and require specialised inpatient care.
• Cost, manufacturing complexity and access will limit how widely the therapy could be offered even if later trials confirm benefit.

What matters now is rigorous testing. Large clinical trials will be needed to measure who benefits, how long effects last, which immune targets work best and how to manage safety. If those trials are positive, CAR‑T could shift thinking about aggressive, refractory MS — offering a pathway toward long‑term disease control for patients with few other options — but it will also raise questions about equity, cost and long‑term immune consequences.